Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Erikstein

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Pharmacogenetics|March 25, 1998
A rare CYP19 (aromatase) variant may increase the risk of breast cancerV N Kristensen, T I Andersen, A Lindblom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2002
The potential for aromatase inhibition in breast cancer preventionP E Lønning, L E Kragh, B Erikstein, et al.
Clinical Therapeutics|May 13, 1999
Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study GroupN Davidson, B Rapoport, B Erikstein, et al.
Experimental Cell Research|September 30, 1999
Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptosisS Naderi, R Blomhoff, J Myklebust, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 10, 2002
Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter studyJ A Söreide, J E Varhaug, H E Fjösne, et al.
The Journal of Biological Chemistry|November 25, 1992
Vitamin A is a key regulator for cell growth, cytokine production, and differentiation in normal B cellsH K Blomhoff, E B Smeland, B Erikstein, et al.
European Journal of Immunology|January 1, 1990
Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separationS Funderud, B Erikstein, H C Asheim, et al.
British Journal of Cancer|December 6, 2000
Screening breast cancer patients for Norwegian ATM mutationsK Laake, P Vu, T I Andersen, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|September 10, 1996
[High-dose therapy with autologous stem cell support in malignant lymphoma and breast cancer. Experiences with hematopoietic stem cells isolate from blood]A Kolstad, H Holte, S Kvaløy, et al.
Pharmacogenetics|November 24, 1998
Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patientsV Nedelcheva Kristensen, T I Andersen, B Erikstein, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Pharmacogenetics|March 25, 1998
A rare CYP19 (aromatase) variant may increase the risk of breast cancerV N Kristensen, T I Andersen, A Lindblom, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2002
The potential for aromatase inhibition in breast cancer preventionP E Lønning, L E Kragh, B Erikstein, et al.
Clinical Therapeutics|May 13, 1999
Comparison of an orally disintegrating ondansetron tablet with the conventional ondansetron tablet for cyclophosphamide-induced emesis in cancer patients: a multicenter, double-masked study. Ondansetron Orally Disintegrating Tablet Emesis Study GroupN Davidson, B Rapoport, B Erikstein, et al.
Experimental Cell Research|September 30, 1999
Lovastatin inhibits G1/S transition of normal human B-lymphocytes independent of apoptosisS Naderi, R Blomhoff, J Myklebust, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|September 10, 2002
Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter studyJ A Söreide, J E Varhaug, H E Fjösne, et al.
The Journal of Biological Chemistry|November 25, 1992
Vitamin A is a key regulator for cell growth, cytokine production, and differentiation in normal B cellsH K Blomhoff, E B Smeland, B Erikstein, et al.
European Journal of Immunology|January 1, 1990
Functional properties of CD19+ B lymphocytes positively selected from buffy coats by immunomagnetic separationS Funderud, B Erikstein, H C Asheim, et al.
British Journal of Cancer|December 6, 2000
Screening breast cancer patients for Norwegian ATM mutationsK Laake, P Vu, T I Andersen, et al.
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke|September 10, 1996
[High-dose therapy with autologous stem cell support in malignant lymphoma and breast cancer. Experiences with hematopoietic stem cells isolate from blood]A Kolstad, H Holte, S Kvaløy, et al.
Pharmacogenetics|November 24, 1998
Single tube multiplex polymerase chain reaction genotype analysis of GSTM1, GSTT1 and GSTP1: relation of genotypes to TP53 tumor status and clinicopathological variables in breast cancer patientsV Nedelcheva Kristensen, T I Andersen, B Erikstein, et al.
Pageof 3